Experience in the Cationorm® use in the treatment of dry eye syndrome in patients after adenoviral keratoconjunctivitis
Vitaly O. Sokolov , Natalya V. Morozova , Galina V. Polovinkina , Mariya L. Borisova , Inna N. Zvontsova , Latifa M. Gasymzade , Yuliya A. Kulikova , Dina R. Shtupun , Ol’ga S. Batynkova
Ophthalmology Reports ›› 2017, Vol. 10 ›› Issue (3) : 61 -66.
Experience in the Cationorm® use in the treatment of dry eye syndrome in patients after adenoviral keratoconjunctivitis
The dry eye syndrome ranges among widespread and persisting ophthalmic diseases. It is also called a disease of civilization. Among the causes particularly often leading to the dry eye syndrome adenoviral infection has to be listed. Over the last years, in Saint Petersburg, an increasing incidence rate of the epidemic adenoviral keratoconjunctivitis is noted, which is proceeding in severe membranous and infiltrative forms, involving the cornea. Occurring therewith secondary dry eye syndrome demands using effective medications. In the article, the experience in Cationorm® (Santen, Japan) clinical use for secondary dry eye syndrome treatment is disclosed.
epidemic adenoviral keratoconjunctivitis / dry eye syndrome / Cationorm® / tear film stability / confocal corneal microscopy
| [1] |
1.Астахов Ю.С., Рикс И.А. Современные методы диагностики и лечения конъюнктивитов. – СПб., 2007. – 68 с. [Astakhov YuS, Riks IA. Sovremennye metody diagnostiki i lecheniya kon’’yunktivitov. Saint Petersburg; 2007. 68 p. (In Russ.)] |
| [2] |
2.Азнабаев М.Т., Гафурова Л.Г., Мальханов В.Б. Аденовирусные и хламидийные заболевания глаз. – Уфа, 1995. – 110 с. [Aznabaev MT, Gafurova LG, Mal’khanov VB. Adenovirusnye i khlamidiynye zabolevaniya glaz. Ufa; 1995. 110 p. (In Russ.)] |
| [3] |
3.Майчук Д.Ю. Вирусные конъюнктивиты и кератоконъюнктивиты // Синдром «красного глаза»: практическое руководство для врачей-офтальмологов. – М., 2010. – С. 31–38. [Maychuk DYu. Virusnye kon’’yunktivity i keratokon’’yunktivity In Sindrom “krasnogo glaza”: prakticheskoe rukovodstvo dlya vrachey-oftal’mologov. Moscow; 2010. P. 31–38. (In Russ.)] |
| [4] |
4.Майчук Д.Ю., Васильева О.А., Пронкин И.А. Результаты длительного применения местных кортикостероидов для лечения инфильтративной формы аденовирусного кератоконъюнктивита // Клиническая офтальмология. – 2014. – № 1. – С. 23–25. [Maychuk DYu, Vasil’yeva OA, Pronkin IA. Rezul’taty dlitel’nogo primeneniya mestnykh kortikosteroidov dlya lecheniya infil’trativnoy formy adenovirusnogo keratokon’’yunktivita. Klinicheskaya oftal’mologiya. 2014;(1):23-25. (In Russ.)] |
| [5] |
5.International Dry Eye Workshop (DEWS). The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul Surface. 2007;5:75-92. doi: 10.1016/S1542-0124(12)70081-2. |
| [6] |
6.Amrane M, et al. Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease – a randomized comparative study. J Fr Ophthalmol. 2014;37(8):589-98. doi: 10.1016/j.jfo.2014.05.001. |
| [7] |
7.Lallemand F, et al. Successfully Improving Ocular Drug Using the Cationic Nanoemulsion, Novasorb. J Drug Devil. 2012: Article ID604204, 16 pages. doi:10.1155/2012/604204604204. |
Sokolov V.O., Morozova N.V., Polovinkina G.V., Borisova M.L., Zvontsova I.N., Gasymzade L.M., Kulikova Y.A., Shtupun D.R., Batynkova O.S.
/
| 〈 |
|
〉 |
PDF
